Mesothelioma News and Research

RSS

Mesothelioma is a form of cancer that is almost always caused by previous exposure to asbestos. In this disease, malignant cells develop in the mesothelium, a protective lining that covers most of the body's internal organs. Most people who develop mesothelioma have worked on jobs where they inhaled asbestos particles, or have been exposed to high levels of asbestos fibers.

Treatment with Tumor Treating Fields triggers downstream anti-tumor cell response, study finds

Novocure announced that a new study published in the Journal of Clinical Investigation (JCI) finds treatment with Tumor Treating Fields (TTFields) mediated cell disruption activates the immune system and triggers an anti-tumor cell response that may be effectively used together with existing immunotherapy approaches in the treatment of solid tumors, with limited systemic toxicity.

25 Feb 2022

Study reveals seven major determinants of mortality risk for patients with COVD-19 and thoracic cancer

The risk of death for patients with SARS-CoV-2 infection and thoracic cancer is based on seven major determinants, according to research published in the Journal of Thoracic Oncology, the official journal of the International Association for the Study of Lung Cancer.

1 Feb 2022

Study points to a new, effective treatment option for patients with mesothelioma

Combining the immunotherapy agent durvalumab with the chemotherapy agents pemetrexed and cisplatin or carboplatin may provide a new treatment option for patients who have inoperable pleural mesothelioma, a cancer of the tissues lining the lungs, according to a phase II clinical trial led by researchers at the Johns Hopkins Kimmel Cancer Center and the Bloomberg~Kimmel Institute for Cancer Immunotherapy.

8 Nov 2021

Promising new therapy for mesothelioma to enter a Phase I clinical trial

Linked to occupational asbestos exposure, malignant mesothelioma (MM) is an aggressive cancer arising primarily from the outer lining of the lungs with a dismal five-year survival rate of only five to 10 percent.

27 Oct 2021

Long working hours are increasingly causing work-related deaths, global report says

Almost two million people worldwide die of work-related causes, according to joint estimates by the World Health Organization and the International Labour Organization, which cite long working hours, pollution and poor conditions as major factors.

2 Oct 2021

Scientists find new possibilities for treatment of lung cancers in 'never smokers'

Despite smoking's well-known role in causing lung cancer, a significant number of patients who develop lung tumors have never smoked. While scientists are still working to understand what spurs cancer in so-called "never-smokers," a study led by scientists at Washington University School of Medicine in St. Louis demonstrates new possibilities for treating these baffling tumors.

1 Oct 2021

Promising data from early clinical trials of new anticancer therapies presented at ESMO Congress 2021

Data from early clinical trials presented at the ESMO Congress 2021 suggest that new anticancer treatments are on the horizon, with a clear emphasis on precision medicine.

24 Sep 2021

Survey: Nearly two-thirds of thoracic oncologists used telehealth for the first time during pandemic

Nearly two-thirds of thoracic oncologists surveyed indicated they used telehealth tools for the first time during the COVID-19 pandemic, according to a report issued at the IASLC 2021 World Conference on Lung Cancer.

12 Sep 2021

Neoadjuvant CPA followed by surgical resection and maintenance atezolizumab meets safety criteria

Neoadjuvant cisplatin and pemetrexed plus atezolizumab followed by surgical resection and maintenance atezolizumab met safety criteria, according to research presented today in OA13: Topics in Pleural Mesothelioma at the IASLC 2021 World Conference on Lung Cancer.

12 Sep 2021

Study finds significant variability in treatment access for patients with malignant pleural mesothelioma

A study of 2,804 patients with stage I to stage III malignant pleural mesothelioma (MPM) found significant variability in access to care and a positive association between multimodality treatment, income levels, and survival outcomes.

12 Sep 2021

Study: Nearly one in five patients with malignant pleural mesothelioma contracted COVID-19

Nearly one in five patients with malignant pleural mesothelioma (MPM) at a Barcelona hospital contracted COVID-19 during the pandemic.

8 Sep 2021

Rice University awarded $4 million CPRIT grant to establish Genetic Design and Engineering Center

Rice University faculty members led by bioengineer Gang Bao have been awarded a $4 million grant by the Cancer Prevention and Research Institute of Texas to establish the Genetic Design and Engineering Center.

20 Aug 2021

Drug combination found to be safe and effective in malignant peritoneal mesothelioma patients

A phase II study led by researchers from The University of Texas MD Anderson Cancer Center found that treatment with atezolizumab and bevacizumab was well-tolerated and resulted in a 40% objective response rate in patients with advanced malignant peritoneal mesothelioma, a rare cancer in the lining of the abdomen.

14 Jul 2021

Selective immunotoxins may help treat liver fibrosis

Chronic alcohol abuse and hepatitis can injure the liver and lead to fibrosis, the buildup of collagen and scar tissue. As a potential approach to treating liver fibrosis, University of California San Diego School of Medicine researchers and their collaborators are looking for ways to stop liver cells from producing collagen.

12 Jul 2021

Mutation-signature–associated metrics predict cancer progression in patients

Oncotarget published "Predicting clinical outcomes using cancer progression associated signatures" which reported somatic mutation signatures are an informative facet of cancer etiology, however they are rarely useful for predicting patient outcome.

28 Jun 2021

In poisoned Montana town, Warren Buffett-owned railroad accuses clinic of Medicare fraud

Patricia Denny and her husband, Jeff, had hoped to one day get an RV and travel the country. Instead, Jeff has been forced into retirement at age 54 by a lung disease caused by the asbestos that's polluted the small town of Libby, Montana, for decades.

29 Apr 2021

Mesothelioma News and Research

Further Reading

Treatment with Tumor Treating Fields triggers downstream anti-tumor cell response, study finds

Study reveals seven major determinants of mortality risk for patients with COVD-19 and thoracic cancer

Study points to a new, effective treatment option for patients with mesothelioma

Promising new therapy for mesothelioma to enter a Phase I clinical trial

Long working hours are increasingly causing work-related deaths, global report says

Scientists find new possibilities for treatment of lung cancers in 'never smokers'

Promising data from early clinical trials of new anticancer therapies presented at ESMO Congress 2021

Survey: Nearly two-thirds of thoracic oncologists used telehealth for the first time during pandemic

Neoadjuvant CPA followed by surgical resection and maintenance atezolizumab meets safety criteria

Study finds significant variability in treatment access for patients with malignant pleural mesothelioma

Study: Nearly one in five patients with malignant pleural mesothelioma contracted COVID-19

Rice University awarded $4 million CPRIT grant to establish Genetic Design and Engineering Center

Drug combination found to be safe and effective in malignant peritoneal mesothelioma patients

Selective immunotoxins may help treat liver fibrosis

Mutation-signature–associated metrics predict cancer progression in patients

In poisoned Montana town, Warren Buffett-owned railroad accuses clinic of Medicare fraud

AI study on aggressive form of cancer could improve patient outcomes

Checkpoint inhibition could offer an effective treatment option for patients with rare cancer

Underrepresentation in genomic databases may affect therapy selection for minority patients

Phase 3 DREAM3R trial opens for malignant pleural mesothelioma

Evaluating new approaches for rare disease genomics

Expanding access to NMR with the Fourier 80 Duo

Advancing Intracellular Delivery with LumiPore®

Latest News